Cure8 research brief
The study suggests more people in Spain are living with IBD even though new cases each year are stable, meaning healthcare systems may face increasing long-term care needs and resource demands.
Clinicians, health system planners, researchers in IBD epidemiology, patient organizations, and adult patients concerned about trends in disease prevalence and service availability.
The researchers used the Spanish Primary Care Clinical Database (BDCAP) and ICPC-2 codes to identify IBD cases and calculated annual incidence and prevalence per 100,000 people. From 2011 to 2024 incidence averaged ~40/100,000 and was stable, while prevalence rose from 244 to 587/100,000 (projected to ~850/100,000 by 2034).
Prevalence rose across age groups and was highest in people aged 60–74 in 2024. The authors describe this as epidemiologic stage 3 (compounding prevalence), implying increasing healthcare needs. The study highlights substantial regional differences within Spain and uses forecasting models (ARIMA) to project future prevalence.
Those projections carry uncertainty but point to continued growth in the number of people living with IBD.
Data come from a national primary care database using diagnostic codes and include model-based forecasts. Coding-based case identification and projection modeling are important limitations to consider.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This large, population-level analysis summarizes long-term global trends in IBD burden and shows rising incidence and persistent geographic and socio-demographic inequalities. Patients and clinicians may see why...
This registry study shows many people with IBD in Kazakhstan had clinically active disease at enrollment and identifies factors linked with active UC and CD. It highlights potential gaps in disease control and...
At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...
